The utilisation of the SGLT-2 inhibitor, dapagliflozin, increased approximately two-fold in the calendar year after its approval for CKD treatment (i.e., from the beginning to the end of 2022; Fig. 3); from 5.3 to 9.3% and from 1.0 to 2.1% in patients with T2D and patients without T2D, respectively. Here, SLC5A2 is linked to chronic kidney disease.